Samsung Biologics Secures 5.5 Trillion Won in Orders This Year, Marking All-Time High

Surpassing Last Year's Order Value in Just 10 Months

Samsung Biologics announced on November 4 that its cumulative order volume for the year has reached 5.5193 trillion won, surpassing last year’s annual order volume of 5.4035 trillion won in just ten months. This marks the largest annual order performance since the company’s founding.

On the same day, Samsung Biologics disclosed that it had signed an expanded contract for contract manufacturing (CMO) worth approximately 275.9 billion won (201.5 million dollars) with a pharmaceutical company based in Europe.

Samsung Biologics Plant 4 Overview. Samsung Biologics

With this contract, the total number of new and expanded contracts announced this year has increased to eight. Notably, the company began the year with its largest-ever contract worth over 2 trillion won in January, and in September, secured an additional contract worth 1.8 trillion won with a U.S.-based pharmaceutical company. By continuously securing large-scale orders from major global clients, Samsung Biologics is maintaining rapid growth.

Currently, Samsung Biologics counts 17 of the world’s top 20 pharmaceutical companies as its clients. Leveraging its overwhelming production capacity, proven quality capabilities, and extensive track record, the company’s cumulative order volume since its founding has surpassed 20 billion dollars.

Samsung Biologics is expanding its production capacity in advance to meet the growing demand for biopharmaceuticals. Plant 5, which began operations in April, is a production facility with a capacity of 180,000 liters, incorporating the optimal operational practices of Plants 1 through 4. With this addition, Samsung Biologics now boasts the world’s largest total production capacity at 784,000 liters.

In terms of quality competitiveness, the company has demonstrated a 99% batch success rate, proving its world-class quality systems. As of October this year, it has obtained a total of 394 manufacturing approvals from major global regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The number of approvals continues to increase each year in line with expanding production capacity and rising order volumes.

John Rim, CEO of Samsung Biologics, stated, “This achievement is the result of customer trust and a commitment to quality-driven management, made possible through close collaboration with our global partners. Going forward, we will continue to strengthen our growth engine and further enhance global customer satisfaction by leveraging our world-class production competitiveness and rapid supply capabilities.”